Bharat Biotech on Friday announced the temporary slowing down of production of COVAXIN across its manufacturing facilities, having completed its supply obligations to procurement agencies and foreseeing the decrease in demand.

"For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities. As all existing facilities were repurposed for the manufacture of COVAXIN, with continuous production during the past year, to meet the public health emergency of COVID-19, these upgrades were due," Bharat Biotech said.